Prognostic factors associated with the response to sunitinib in patients with metastatic renal cell carcinoma

Current Oncology

C. Ordu¹  H.M. Tunc¹  M. Ekenel¹  E. Darendeliler¹  I. Kilicaslan¹  U. Varol²  S. Bavbek¹  I. Yildiz¹  F. Sen¹  L. Kilic¹  M. Basaran¹ 

[1] Istanbul University;Izmir Katip Celebi University

关键词: Metastatic renal cell carcinoma;    prognostic factors;    sarcomatoid features;    first-line therapy;    vascular endothelial growth factor;    vegf antagonist;   

DOI  :  

学科分类：肿瘤学

来源: Multimed, Inc.

【 摘 要 】

Objective We investigated the prognostic clinicopathologic factors associated with overall survival (os) and progression-free survival (pfs) in the once-daily continuous administration of first-line sunitinib in a consecutive cohort of Turkish patients with metastatic renal cell carcinoma (rcc). Methods The study enrolled 77 Turkish patients with metastatic rcc who received sunitinib in a continuous once-daily dosing regimen between April 2006 and April 2011. Univariate analyses were performed using the log-rank test. Results Median follow-up was 18.5 months. In univariate analyses, poor pfs and os were associated with 4 of the 5 factors in the Memorial Sloan–Kettering Cancer Center (mskcc) score: Eastern Cooperative Oncology Group performance status of 2 or higher, low hemoglobin, high corrected serum calcium, and high lactate dehydrogenase. In addition to those factors, hypoalbuminemia, more than 2 metastatic sites, liver metastasis, non–clear cell histology, and the presence of sarcomatoid features on pathology were also associated with poor pfs; and male sex, hypoalbuminemia, prior radiotherapy, more than 2 metastatic sites, lung metastasis, nuclear grade of 3 or 4 for the primary tumour, and the presence of sarcomatoid features were also associated with poorer os. The application of the mskcc model distinctly separated the pfs and os curves ( p< 0.001). Conclusions Our study identified prognostic factors for pfs and os with the use sunitinib as first-line metastatic rcc therapy and confirmed that the mskcc model still appears to be valid for predicting survival in metastatic rcc in the era of molecular targeted therapy.

【 授权许可】

Unknown